Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them,...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2009-03-01
|
| Saila: | Hematology Reports |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.pagepress.org/journals/index.php/hr/article/view/4 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|